{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:34:41Z","timestamp":1793388881900,"version":"4.5.0"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"name":"Department of Veterans Affairs, the Seattle Institute for Biomedical and Clinical Research, and the University of Washington","id":[{"id":"https:\/\/ror.org\/04c91wj10","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001906","name":"Washington Research Foundation","doi-asserted-by":"crossref","award":["Postdoctoral Fellowship"],"award-info":[{"award-number":["Postdoctoral Fellowship"]}],"id":[{"id":"10.13039\/100001906","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>\n                    Effective SARS-CoV-2 antiviral drugs are desperately needed. The SARS-CoV-2 main protease (Mpro) appears as an attractive target for drug development. We show that the existing pharmacopeia contains many drugs with potential for therapeutic repurposing as selective and potent inhibitors of SARS-CoV-2 Mpro. We screened a collection of ~6,070 drugs with a previous history of use in humans for compounds that inhibit the activity of Mpro\n                    <jats:italic>in vitro<\/jats:italic>\n                    and found ~50 compounds with activity against Mpro. Subsequent dose validation studies demonstrated 8 dose responsive hits with an IC50 \u2264 50 \u03bcM. Hits from our screen are enriched with hepatitis C NS3\/4A protease targeting drugs including boceprevir, ciluprevir. narlaprevir, and telaprevir. This work suggests previous large-scale commercial drug development initiatives targeting hepatitis C NS3\/4A viral protease should be revisited because some previous lead compounds may be more potent against SARS-CoV-2 Mpro than boceprevir and suitable for rapid repurposing.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0245962","type":"journal-article","created":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T15:33:48Z","timestamp":1612193628000},"page":"e0245962","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":54,"title":["A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease"],"prefix":"10.1371","volume":"16","author":[{"given":"Jeremy D.","family":"Baker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikki L.","family":"Uhrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald C.","family":"Kraemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason E.","family":"Love","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2252-7634","authenticated-orcid":true,"given":"Brian C.","family":"Kraemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"key":"pone.0245962.ref001","first-page":"1","article-title":"Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study","volume":"2020","author":"W Zhao","journal-title":"AJR Am J Roentgenol"},{"issue":"8","key":"pone.0245962.ref002","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","article-title":"SARS and MERS: recent insights into emerging coronaviruses","volume":"14","author":"E de Wit","year":"2016","journal-title":"Nat Rev Microbiol"},{"key":"pone.0245962.ref003","first-page":"95","article-title":"Viral and cellular proteins involved in coronavirus replication","volume":"287","author":"ST Shi","year":"2005","journal-title":"Curr Top Microbiol Immunol"},{"issue":"7835","key":"pone.0245962.ref004","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","volume":"587","author":"D Shin","year":"2020","journal-title":"Nature"},{"key":"pone.0245962.ref005","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors","author":"L Zhang","year":"2020","journal-title":"Science"},{"key":"pone.0245962.ref006","article-title":"Structure of M(pro) from COVID-19 virus and discovery of its inhibitors","author":"Z Jin","year":"2020","journal-title":"Nature"},{"issue":"9","key":"pone.0245962.ref007","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1517\/13543784.11.9.1295","article-title":"Atazanavir: a novel HIV-1 protease inhibitor","volume":"11","author":"PJ Piliero","year":"2002","journal-title":"Expert opinion on investigational drugs"},{"issue":"18","key":"pone.0245962.ref008","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1517\/14656566.2013.850074","article-title":"Simeprevir for the treatment of chronic hepatitis C","volume":"14","author":"DM You","year":"2013","journal-title":"Expert opinion on pharmacotherapy"},{"issue":"8","key":"pone.0245962.ref009","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"TT Ashburn","year":"2004","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"pone.0245962.ref010","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1358\/dnp.2009.22.2.1303818","article-title":"The value of drug repositioning in the current pharmaceutical market","volume":"22","author":"EL Tobinick","year":"2009","journal-title":"Drug News Perspect"},{"issue":"7089","key":"pone.0245962.ref011","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature04657","article-title":"A small-molecule screen in C. elegans yields a new calcium channel antagonist","volume":"441","author":"TC Kwok","year":"2006","journal-title":"Nature"},{"issue":"7169","key":"pone.0245962.ref012","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nature05991","article-title":"An antidepressant that extends lifespan in adult Caenorhabditis elegans","volume":"450","author":"M Petrascheck","year":"2007","journal-title":"Nature"},{"issue":"4","key":"pone.0245962.ref013","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nm.4306","article-title":"The Drug Repurposing Hub: a next-generation drug library and information resource","volume":"23","author":"SM Corsello","year":"2017","journal-title":"Nat Med"},{"key":"pone.0245962.ref014","unstructured":"D. Wishart CK, V. Law. Drug Bank: Open Data Drug & Drug Target Database 2012 [cited 2012 November 21]. Available from: http:\/\/www.drugbank.ca\/stats."},{"key":"pone.0245962.ref015","article-title":"Substrate specificity profiling of SARS-CoV-2 main protease enables design of activity-based probes for patient-sample imaging","author":"KG Wioletta Rut","year":"2020"},{"issue":"10","key":"pone.0245962.ref016","doi-asserted-by":"crossref","first-page":"e13197","DOI":"10.1371\/journal.pone.0013197","article-title":"Profiling of substrate specificity of SARS-CoV 3CL","volume":"5","author":"CP Chuck","year":"2010","journal-title":"PLoS One"},{"issue":"6497","key":"pone.0245962.ref017","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"W Dai","year":"2020","journal-title":"Science"},{"issue":"1","key":"pone.0245962.ref018","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1021\/ar700109k","article-title":"Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection","volume":"41","author":"FG Njoroge","year":"2008","journal-title":"Acc Chem Res"},{"issue":"11","key":"pone.0245962.ref019","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1517\/17460441.2013.843525","article-title":"The discovery and development of boceprevir","volume":"8","author":"DP Rotella","year":"2013","journal-title":"Expert opinion on drug discovery"},{"issue":"2","key":"pone.0245962.ref020","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1021\/ml9000276","article-title":"Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor","volume":"1","author":"A Arasappan","year":"2010","journal-title":"ACS medicinal chemistry letters"},{"issue":"4","key":"pone.0245962.ref021","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1111\/jvh.12012","article-title":"Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up","volume":"20","author":"DM Hotho","year":"2013","journal-title":"J Viral Hepat"},{"issue":"4","key":"pone.0245962.ref022","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2006.07.013","article-title":"Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study","volume":"131","author":"HW Reesink","year":"2006","journal-title":"Gastroenterology"},{"issue":"1","key":"pone.0245962.ref023","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1053\/j.gastro.2006.12.011","article-title":"Combination therapy with telaprevir and pegylated interferon suppresses both wild-type and resistant hepatitis C virus","volume":"132","author":"L Lang","year":"2007","journal-title":"Gastroenterology"},{"issue":"7","key":"pone.0245962.ref024","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1021\/ja512751q","article-title":"Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field","volume":"137","author":"L Wang","year":"2015","journal-title":"J Am Chem Soc"},{"issue":"6","key":"pone.0245962.ref025","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1021\/acs.jmedchem.6b01881","article-title":"Prospective Evaluation of Free Energy Calculations for the Prioritization of Cathepsin L Inhibitors","volume":"60","author":"B Kuhn","year":"2017","journal-title":"J Med Chem"},{"issue":"3","key":"pone.0245962.ref026","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)","volume":"19","author":"G Li","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"pone.0245962.ref027","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12250-015-3711-3","article-title":"Recent progress in the discovery of inhibitors targeting coronavirus proteases","volume":"31","author":"H Wang","year":"2016","journal-title":"Virologica Sinica"},{"issue":"2","key":"pone.0245962.ref028","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2174\/1574891X113089990017","article-title":"Recent developments on coronavirus main protease\/3C like protease inhibitors","volume":"8","author":"Q Zhao","year":"2013","journal-title":"Recent patents on anti-infective drug discovery"},{"issue":"3","key":"pone.0245962.ref029","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"CM Chu","year":"2004","journal-title":"Thorax"},{"key":"pone.0245962.ref030","doi-asserted-by":"crossref","first-page":"129","DOI":"10.12688\/f1000research.22457.2","article-title":"Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates","volume":"9","author":"YW Chen","year":"2020","journal-title":"F1000Research"},{"issue":"6","key":"pone.0245962.ref031","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20201256","article-title":"Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy","volume":"40","author":"A Shamsi","year":"2020","journal-title":"Bioscience reports"},{"issue":"19","key":"pone.0245962.ref032","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of Covid-19\u2014Final Report","volume":"383","author":"JH Beigel","year":"2020","journal-title":"N Engl J Med"},{"issue":"13","key":"pone.0245962.ref033","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"F Poordad","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0245962.ref034","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/hep.23899","article-title":"Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients","volume":"52","author":"J de Bruijne","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"pone.0245962.ref035","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1128\/AAC.00135-10","article-title":"Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease","volume":"54","author":"X Tong","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0245962.ref036","author":"M Mohammad","journal-title":"Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2"},{"issue":"8","key":"pone.0245962.ref037","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","article-title":"Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease","volume":"30","author":"C Ma","year":"2020","journal-title":"Cell Res"},{"issue":"12","key":"pone.0245962.ref038","doi-asserted-by":"crossref","first-page":"6236","DOI":"10.1128\/AAC.01578-13","article-title":"In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir","volume":"57","author":"M Jiang","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"pone.0245962.ref039","doi-asserted-by":"crossref","first-page":"5289","DOI":"10.1128\/AAC.00780-12","article-title":"Characterization of resistance to the protease inhibitor GS-9451 in hepatitis C virus-infected patients","volume":"56","author":"H Dvory-Sobol","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"pone.0245962.ref040","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.coph.2004.07.003","article-title":"Strategies for hepatitis C therapeutic intervention: now and next","volume":"4","author":"SL Tan","year":"2004","journal-title":"Curr Opin Pharmacol"},{"key":"pone.0245962.ref041","doi-asserted-by":"crossref","first-page":"104541","DOI":"10.1016\/j.antiviral.2019.104541","article-title":"Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase","volume":"169","author":"AJ Brown","year":"2019","journal-title":"Antiviral Res"},{"issue":"3","key":"pone.0245962.ref042","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"M Wang","year":"2020","journal-title":"Cell Res"},{"issue":"6","key":"pone.0245962.ref043","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1002\/hep.23192","article-title":"Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients","volume":"50","author":"S Susser","year":"2009","journal-title":"Hepatology"},{"issue":"7","key":"pone.0245962.ref044","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"RA Friesner","year":"2004","journal-title":"J Med Chem"},{"issue":"7","key":"pone.0245962.ref045","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/jm030644s","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening","volume":"47","author":"TA Halgren","year":"2004","journal-title":"J Med Chem"},{"issue":"2","key":"pone.0245962.ref046","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays","volume":"4","author":"JH Zhang","year":"1999","journal-title":"J Biomol Screen"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0245962","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T15:34:08Z","timestamp":1612193648000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0245962"}},"subtitle":[],"editor":[{"given":"Luis M.","family":"Schang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0245962","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.07.10.197889","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,1]]}}}